A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...